Full-Time

Sr. Engineer

Conjugation Development and Clinical Manufacturing

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$152k - $170kAnnually

Senior

San Carlos, CA, USA

Onsite position in San Carlos, CA.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Chemical/Biochemical Engineering or similar, with 2+ years of industry experience; MS with 5+ years of industry experience; or BS with 10+ years of industry experience.
  • Both practical experience with and theoretical knowledge of engineering principles involved in scaling processes from development lab to pilot / manufacturing plant.
  • Working knowledge of the requirements of GMP manufacturing, preferably with hands on GMP experience through either a Manufacturing or MSAT role.
  • Experience working with CMOs highly desired; ability to effectively transfer processes to CMO, and to oversee development and manufacturing activities performed at CMO; ability to travel to CMO (some international travel required) to perform person-in-plant oversight activities.
  • Solid understanding of the principals of DoE (Design of Experiments); practical experience with DoE software; proficient in the design and interpretation of statistically modelled experiments.
  • Experience with late-stage process development activities such as risk assessments (e.g., FMEA) and identification of CPPs and CQAs is a plus.
  • Experience writing IND sections is a plus.
  • Bioconjugate or protein purification knowledge and experience, including expertise in tangential flow filtration (TFF), process scaling and optimization, and reactor scale up is a plus.
  • Demonstrated success working in a cross-functional team environment on multiple projects; ability to work both on a team (as member and/or leader) and independently to deliver results.
  • Strong interpersonal skills, with excellent written and verbal communication skills.
Responsibilities
  • Help to define the scope and strategy of late-stage process development activities such as process characterization and development of scale-down models.
  • In concert with CMO, help to define the scope and strategy of PPQ activities.
  • Take the lead in scale-up activities to support manufacture of Phase 3 and Commercial scale quantities of the VAX-24 Conjugate Drug Substances.
  • In concert with CMO, identify and implement the appropriate equipment required to perform late-stage manufacturing.
  • Contribute to CMO Manufacturing oversight via document review, person in plant responsibilities, and troubleshooting when necessary.
  • Facilitate cross-functional process risk analysis using appropriate tools such as FMEA, leading to the identification of CPPs and CQAs.
  • Present/communicate data to the Conjugation Development team as well as broader CMC team.
  • Serve as a guide and mentor to junior team members.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?